

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 18, 2025

NALM-6

RRID:CVCL_0092

Type: Cell Line

Proper Citation

(RRID:CVCL_0092)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0092

Proper Citation: (RRID:CVCL_0092)

Sex: Male

Defining Citation: [PMID:83966](#), [PMID:155647](#), [PMID:2140233](#), [PMID:2415623](#), [PMID:2783384](#), [PMID:2939141](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:8847894](#), [PMID:9067587](#), [PMID:9510473](#), [PMID:9680106](#), [PMID:9738977](#), [PMID:10490826](#), [PMID:10695022](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:11416159](#), [PMID:11986953](#), [PMID:15843827](#), [PMID:16405397](#), [PMID:16408098](#), [PMID:16969076](#), [PMID:20103924](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20575032](#), [PMID:20922763](#), [PMID:22460905](#), [PMID:23596518](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29786757](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31243274](#), [PMID:31978347](#), [PMID:34823530](#), [PMID:35124168](#), [PMID:35354797](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: Deep quantitative proteome analysis., Omics: DNA methylation analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: NALM-6

Synonyms: Nalm-6, NALM 6, Nalm 6, NALM6, Nalm6, NALM-6-M1

Cross References: BTO:BTO_0003288, CLO:CLO_0007938, CLO:CLO_0050970, EFO:EFO_0002245, CLDB:cl3631, CLDB:cl3632, AddexBio:C0003030/5015, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:273, BioSample:SAMN03472035, BioSample:SAMN03473163, BioSample:SAMN03473413, BioSample:SAMN10988491, cancercellines:CVCL_0092, Cell_Model_Passport:SIDM00429, ChEMBL-Cells:ChEMBL3307559, ChEMBL-Targets:ChEMBL614187, CLS:300297, Cosmic:801722, Cosmic:850385, Cosmic:889112, Cosmic:908158, Cosmic:919147, Cosmic:991553, Cosmic:998708, Cosmic:999748, Cosmic:1012106, Cosmic:1037711, Cosmic:1070706, Cosmic:1093787, Cosmic:1130246, Cosmic:1191699, Cosmic:1483361, Cosmic:1509198, Cosmic:1524810, Cosmic:2491082, Cosmic:2649232, Cosmic-CLP:908158, DepMap:ACH-000938, DSMZ:ACC-128, DSMZCellDive:ACC-128, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:908158, GEO:GSM236797, GEO:GSM236833, GEO:GSM887347, GEO:GSM888423, GEO:GSM1670142, GEO:GSM5137734, IARC_TP53:21527, IGRhCellID:NALM6, LiGeA:CCLE_665, LINCS_LDP:LCL-1007, Lonza:812, NCBI_Iran:C212, PharmacDB:NALM6_980_2019, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL_0092, PubChem_Cell_line:CVCL_0092, RCB:RCB1933, TKG:TKG 0413, Wikidata:Q54907426

ID: CVCL_0092

Record Creation Time: 20250131T201448+0000

Record Last Update: 20250131T203121+0000

Ratings and Alerts

No rating or validation information has been found for NALM-6.

No alerts have been found for NALM-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 501 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://www.fdi-lab.org/sci-crunch).

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. *Molecular cancer therapeutics*, 23(5), 683.

Chaudhry S, et al. (2024) Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition. *Leukemia*, 38(9), 1894.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. *Cell stem cell*, 31(9), 1376.

Shen Y, et al. (2024) Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I. *British journal of pharmacology*, 181(21), 4262.

Chen HC, et al. (2024) Novel immunotherapeutics against LGR5 to target multiple cancer types. *EMBO molecular medicine*, 16(9), 2233.

Lei W, et al. (2024) Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. *Cell discovery*, 10(1), 5.

Kowalik M, et al. (2024) Anticancer Study on IrIII and RhIII Half-Sandwich Complexes with the Bipyridylsulfonamide Ligand. *Inorganic chemistry*, 63(2), 1296.

Alieva M, et al. (2024) BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response. *Nature protocols*, 19(7), 2052.

Hlozkova K, et al. (2024) Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase. *Cancer letters*, 605, 217242.

Baldwin JG, et al. (2024) Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. *Cell*.

Touarin P, et al. (2024) Pre-B cell receptor acts as a selectivity switch for galectin-1 at the pre-B cell surface. *Cell reports*, 43(8), 114541.

von Palffy S, et al. (2023) The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML. *Blood advances*, 7(7), 1204.

Kerketta R, et al. (2023) Spatial Stochastic Model of the Pre-B Cell Receptor. *IEEE/ACM transactions on computational biology and bioinformatics*, 20(1), 683.

Liu J, et al. (2023) Exploring the mechanism of physcion-1-O- β -D-monoglucoside against acute lymphoblastic leukaemia based on network pharmacology and experimental validation. *Heliyon*, 9(3), e14009.

Foss DV, et al. (2023) Peptide-mediated delivery of CRISPR enzymes for the efficient editing

of primary human lymphocytes. Nature biomedical engineering, 7(5), 647.

Klysz DD, et al. (2023) Inosine Induces Stemness Features in CAR T cells and Enhances Potency. bioRxiv : the preprint server for biology.

He B, et al. (2023) Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Frontiers in immunology, 14, 1130442.

Pourzia AL, et al. (2023) Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. Cell death & disease, 14(4), 267.

Zimmerman JAO, et al. (2023) PI3K γ inhibition potentiates glucocorticoids in B-ALL by decreased receptor phosphorylation and enhanced gene regulation. bioRxiv : the preprint server for biology.

Ukrainskaya VM, et al. (2023) CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. Scientific reports, 13(1), 463.